Melanotan 2 Nasal Spray

What Melanotan 2 Is

Melanotan 2 is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (α-MSH), with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2. It carries CAS number 121062-08-6, molecular formula C50H69N15O9, and a molecular weight of approximately 1,024.2 g/mol.

Unlike Melanotan 1 (afamelanotide), which is a selective MC1R agonist, Melanotan 2 is a nonselective melanocortin receptor agonist — it activates MC1R (the receptor most associated with pigmentation), MC3R, and MC4R. MC4R activation is also implicated in appetite and sexual-function signalling pathways, which is why Melanotan 2's receptor profile differs meaningfully from Melanotan 1's, and why research and case-report literature on the two peptides is not interchangeable.

What Current Research Says

The original human pharmacology data comes from a 1996 pilot phase-I clinical study (Dorr et al., Life Sciences) that evaluated Melanotan-II as a melanotropic peptide and reported its receptor-agonism and pigmentation effects in a small clinical cohort — this is decades-old, small-scale clinical pharmacology data, not a modern safety or efficacy trial, and it does not describe an unlicensed, non-pharmaceutical-grade product purchased online.

Because Melanotan 2 is nonselective across MC1R, MC3R, and MC4R, published case-report literature has documented adverse events linked to its receptor activity, including priapism (Devlin et al., 2013, Clinical Toxicology; Dreyer et al., 2019, BMJ Case Reports) and a case report of melanoma occurring in a melanotan user with subsequent pigmented-lesion changes (Paurobally et al., 2011, British Journal of Dermatology). These are case reports describing adverse events in individual patients following use of unregulated melanotan products, not a characterisation of this specific research-use listing, and they are not a substitute for a controlled trial — but they are directly relevant to why melanocortin receptor agonists of this kind remain an active subject of pharmacological research rather than an established cosmetic product.

Regulatory and Safety Status in the UK

Melanotan 2 is not a controlled drug under the Misuse of Drugs Act 1971. It is classified by the MHRA as a medicinal product within the meaning of the Human Medicines Regulations 2012 (SI 2012/1916), and no melanotan product holds a UK marketing authorisation. UK regulators have previously issued public safety warnings specifically about melanotan products marketed online as unlicensed “tanning injections”, citing concerns about unverified sourcing, inconsistent purity, and the adverse events described in the case-report literature above. This listing is supplied strictly for laboratory and in-vitro research use, is not sold as a cosmetic or tanning product, and is not licensed, assessed, or approved by the MHRA for any human use, application, or benefit.

Specifications

Purity, Batch Testing and Certificate of Analysis Standards

Every Melanotan 2 Nasal Spray unit offered for sale is supplied with third-party analytical documentation confirming peptide purity, the analytical method used (typically HPLC or mass spectrometry), the batch or lot number, and the issuing laboratory. Purity testing verifies chemical identity and concentration; it does not address the receptor-mediated effects described in the case-report literature above, which relate to the compound's pharmacology rather than its purity. See our contact page to request a Certificate of Analysis for a specific batch.

Sourcing and Verification

Because Melanotan 2 is widely marketed online outside a research-use framing, verifying a supplier matters more than usual. Before ordering, check that the listing states research-use status clearly rather than implying a cosmetic or tanning benefit, that batch documentation is offered rather than promised only “on request,” and that the compound's identity (CAS number, molecular formula) is independently verifiable against a source such as PubChem. Melanotan 2 Nasal Spray is offered for sale on this basis, with documentation available per batch. Researchers examining other cosmetic-adjacent research peptides may also find the Glow Skin 112mg blend relevant, and the full catalogue is browsable on the research products page.